Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03361176 · ClinicalTrials.gov registry record · Phase 4

Kybella With Triamcinolone

A Phase 4 study of Adiposity, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
2
Study locations

NCT03361176: Completed Phase 4 study of Adiposity, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

NCT03361176 is a Phase 4 study of Adiposity that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 30 participants, below the 98-participant average among 11 other Adiposity trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03361176, a Phase 4 study of Adiposity, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

Primary Outcome

Change in efficacy will be measured from Baseline to 90 days post final treatment using a 5-point Clinician-Reported Submental Fat Rating Scale ranging from Absent (score of 0) to Extreme submental convexity (score of 4)

Conditions Studied

Interventions

  • DRUG Injectable sodium deoxycholate
  • COMBINATION_PRODUCT Injectable sodium deoxycholate with Triamcinolone acetate

Study Locations (2)

California

  • West Dermatology Research Center - San Diego

Maryland

  • Maryland Dermatology Laser, Skin and Vein Institute - Hunt Valley

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-03-26
Est. Completion 2018-12-18
Phase Phase 4

What the finished NCT03361176 record still lists

NCT03361176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 98-participant average among 11 other Adiposity trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Adiposity appearing as the primary indexed condition, and to 2 interventions - of which Injectable sodium deoxycholate is the first listed.

NCT03361176 reports a single indexed study location in California, Maryland.

Frequently Asked Questions

What is clinical trial NCT03361176 about?

NCT03361176 is a clinical study titled "Kybella With Triamcinolone". This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

What is the current status of trial NCT03361176?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-03-26. Estimated completion is 2018-12-18.

What conditions does trial NCT03361176 study?

This clinical trial studies the following conditions: Adiposity.

What interventions are being tested in trial NCT03361176?

The interventions under investigation include: Injectable sodium deoxycholate (DRUG), Injectable sodium deoxycholate with Triamcinolone acetate (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03361176?

This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03361176 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adiposity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03361176's enrollment target sits among peer trials

30 8th of 11 higher than 4 of 11 other Adiposity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adiposity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03361176, the US trial registry maintained by the National Library of Medicine. NCT03361176 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.